Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.
A glioblastoma multiforme xenograft was established in athymic nude mice via inoculation of glioblastoma cells that stably express luciferase (U87MG-LucNeo), and was monitored weekly using bioluminescence imaging (BLI). In the control groups, a steep rise in the signal was associated with the death of mice. As an adjuvant therapy, cetuximab (0.5 mg, two times) was intraperitoneally administered 4 weeks after nitrosourea treatment. For a salvage therapy, cetuximab (0.5 mg, two times) was intraperitoneally administered when recovery of the bioluminescence signal was detected after nitrosourea monotherapy. The antitumor effects of cetuximab adjuvant therapy were superior to those of nitrosourea monotherapy and cetuximab salvage therapy. This finding was consistent with the results from a survival comparison among nitrosourea monotherapy, adjuvant and salvage therapy with cetuximab. These results suggest that BLI could be used as a simple tool for predicting the efficacy of various anticancer treatments in mouse models of brain tumors. The administration of cetuximab as an adjuvant to the conventional chemotherapeutic agent is more efficient than salvage therapy.
Yang
Seung-Ho
SH
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Hong
Yong-Kil
YK
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea.
Jeun
Sin-Soo
SS
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea.
Kim
Il Sup
IS
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Hong
Jae Taek
JT
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Sung
Jae Hoon
JH
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Son
Byung Chul
BC
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Lee
Sang Won
SW
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
Kim
Moon-Chan
MC
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea.
Lee
Kwan-Sung
KS
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea. nslk@catholic.ac.kr.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D000068818:Cetuximab; D004195:Disease Models, Animal; D005909:Glioblastoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D008130:Lomustine / Q000627:therapeutic use; D049449:Luminescence; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D016019:Survival Analysis; D013997:Time Factors; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D008130:Lomustine; D000068818:Cetuximab